Core Viewpoint - The company is focused on advancing innovative treatments for cancer and immune diseases, showcasing its latest developments in the ATTC platform and late-stage pipeline candidates [1] Group 1: R&D Progress - The company shared key advancements in its innovative cancer and immune disease treatments during an investor meeting [1] - The ATTC platform is expected to redefine precision treatment for cancer, addressing unmet medical needs in these fields [1] Group 2: Leadership Insights - Dr. Shi Ming, the company's R&D head and Chief Medical Officer, emphasized the mission to meet critical unmet medical needs in cancer and immune diseases [1] - The company is confident in its ability to provide transformative treatment options for patients globally, supported by a robust product pipeline and collaboration strategies [1]
和黄医药(00013.HK)举办最新研发进展投资者会议分享产品管线及业务进展